RCUS — Arcus Biosciences, Inc.
—
NYSE ·
Health Care ·
Pharmaceuticals ·
CIK 1724521 ·
Last close
$16.39
Market Cap
$2.36B
52W High
$31.74
52W Low
$16.33
ADV30
2,228,915
Next earnings
2026-11-04
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 9,000,000 | — | -131,000,000 | -128,000,000 | 818,000,000 | 151,000,000 | 460,000,000 |
| Jun 2026 | 41,000,000 | — | -96,000,000 | -91,000,000 | 924,000,000 | 150,000,000 | 460,000,000 |
| Mar 2026 | 17,000,000 | — | -134,000,000 | -128,000,000 | 997,000,000 | 201,000,000 | 473,000,000 |
| Dec 2025 | 33,000,000 | — | -114,000,000 | -106,000,000 | 1,139,000,000 | 222,000,000 | 508,000,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-465,000,000
Investing CF
$66,000,000
Financing CF
$312,000,000
CapEx
$-2,000,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.63
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,832,000,000
Inventory
—
Receivables
$23,000,000
ST Investments
$479,000,000
EBIT TTM
$-442,000,000
Pretax Income TTM
$-453,000,000
Interest Exp TTM
$11,000,000
Analysts
12
Yahoo Snapshot (yfinance, live)
Total Revenue
$100,000,000
EBITDA
$-465,000,000
Free Cash Flow
$-274,750,016
Enterprise Value
$2,243,148,544
Total Cash
$630,000,000
Total Debt
$241,000,000
Shares Out
143,990,614
Trailing EPS
$-3.64
Book Value
$2.81
ROE
-114.1%
ROA
-33.1%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 247,000,000 | -386,000,000 | -353,000,000 | 1,139,000,000 | 508,000,000 | 631,000,000 | -482,000,000 |
| Dec 2024 | 258,000,000 | -310,000,000 | -283,000,000 | 1,150,000,000 | 665,000,000 | 485,000,000 | -170,000,000 |
| Dec 2023 | 117,000,000 | -340,000,000 | -307,000,000 | 1,095,000,000 | 633,000,000 | 462,000,000 | -306,000,000 |
| Dec 2022 | 112,000,000 | -280,000,000 | -267,000,000 | 1,345,000,000 | 688,000,000 | 657,000,000 | 438,000,000 |
TTM Snapshot
Revenues TTM
$117,000,000
NetIncome TTM
$-460,000,000
OpCashFlow TTM
—
Assets (Latest)
$924,000,000
Forward EPS
$-3.13
Max Pain — expiry 2026-12-18
max pain strike: $20.00 · spot: $15.76 · call oi: 1,158 · put oi: 1,359
Expected Move to 2026-12-18:
±$3.73
(23.64%) —
implied range
$12.04 –
$19.49
· ATM straddle on $15.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| NAMS | NewAmsterdam Pharma Co N.V. | $2.33B | $19.39 | — |
| GLPGF | Lakefront Biotherapeutics NV | $2.30B | $35.15 | — |
| PBH | Prestige Consumer Healthcare Inc. | $2.29B | $48.22 | — |
| PHVS | Pharvaris N.V. | $2.27B | $32.28 | — |
| LKFT | Lakefront Biotherapeutics NV | $2.25B | $34.39 | — |
News headlines (Yahoo Finance, 1h cache)
Arcus Biosciences to Participate in Two Upcoming Investor Conferences
2026-11-18 21:05 · Yahoo
Caught Out By Arcus Biosciences' Slide? Here's What Bears Saw
2026-11-18 20:11 · Yahoo
Arcus Biosciences, Inc. (RCUS) Reports Q3 Loss, Lags Revenue Estimates
2026-11-04 23:45 · Yahoo
Arcus Biosciences Reports Third-Quarter 2026 Financial Results and Provides a Pipeline Update
2026-11-04 21:05 · Yahoo
Arcus Biosciences to Participate in the Jefferies Global Healthcare Conference 2026 in London
2026-11-02 21:05 · Yahoo
Arcus Biosciences Announces New Employment Inducement Grants
2026-10-26 20:35 · Yahoo
How Investors May Respond To Arcus Biosciences (RCUS) $250 Million Share Sale
2026-10-24 21:13 · Yahoo
Arcus Biosciences (RCUS) Stock Looks Stretched As Casdatifan Trial Data Impresses
2026-10-24 19:09 · Yahoo
Arcus Biosciences Announces Pricing of $250 Million Public Offering of Common Stock
2026-10-22 02:53 · Yahoo
Arcus Biosciences stock falls on public offering announcement
2026-10-21 22:32 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.